Efficacy of afoxolaner in a clinical field study in dogs naturally infested with Sarcoptes scabiei.
The acaricidal efficacy of afoxolaner (NexGard(®), Merial) was evaluated against Sarcoptes scabiei var. canis in a field efficacy study, when administered orally at a minimum dose of 2.5 mg/kg to dogs naturally infested with the mites. Twenty mixed-breed dogs of either sex (6 males and 14 females), aged over 6 months and weighing 4-18 kg, were studied in this randomised controlled field efficacy trial. Dogs, naturally infested with Sarcoptes scabiei var. canis confirmed by skin scrapings collected prior to allocation, were randomly divided into two equal groups. Dogs in Group 1 were not treated. Dogs in Group 2 were treated on Days 0 and 28. On Days 0 (pre-treatment), 28 (pre-treatment) and 56, five skin scrapings of similar size were taken from different sites with lesions suggestive of sarcoptic mange. The extent of lesions was also recorded on Days 0, 28 and 56, and photographs were taken. Dogs treated orally with afoxolaner had significantly (p < 0.001) lower mite counts than untreated control animals at Days 28 and 56 with no mites recovered from treated dogs at these times (100% efficacy based on mite counts). In addition, dogs treated with NexGard had significantly (p < 0.05) better lesion resolution at Day 56 than Day 0; no treated dog showed pruritus compared to 7/10 dogs in the control group, 1/9 treated dogs had crusts compared to 5/10 controls and 8/9 dogs recovered 90% of hairs on lesions compared to 0/10 control dogs.
Merial S.A.S., 29 avenue Tony Garnier, 69630 Lyon, France.
Frédéric
F
Beugnet
Clinvet International (Pty) Ltd, PO Box 11186, 9321 Universitas, South Africa.
Christa
C
de Vos
Clinvet International (Pty) Ltd, PO Box 11186, 9321 Universitas, South Africa.
Julian
J
Liebenberg
Merial S.A.S., 29 avenue Tony Garnier, 69630 Lyon, France.
Lénaïg
L
Halos
Merial S.A.S., 29 avenue Tony Garnier, 69630 Lyon, France.
Diane
D
Larsen
Clinvet International (Pty) Ltd, PO Box 11186, 9321 Universitas, South Africa.
Josephus
J
Fourie
D056810:Acaricides / Q000627:therapeutic use*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D005260:Female; D007555:Isoxazoles / Q000627:therapeutic use*; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D012520:Sarcoptes scabiei / Q000187:drug effects / Q000254:growth & development; D012532:Scabies / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D012867:Skin / Q000469:parasitology
D056810:Acaricides; D007555:Isoxazoles; D009281:Naphthalenes; C000589002:afoxolaner